百日咳鼻用疫苗。

IF 6.6 2区 医学 Q1 IMMUNOLOGY Current Opinion in Immunology Pub Date : 2023-10-01 DOI:10.1016/j.coi.2023.102355
Pauline Schmitt , Lisa Borkner , Seyed Davoud Jazayeri , Karen N McCarthy , Kingston HG Mills
{"title":"百日咳鼻用疫苗。","authors":"Pauline Schmitt ,&nbsp;Lisa Borkner ,&nbsp;Seyed Davoud Jazayeri ,&nbsp;Karen N McCarthy ,&nbsp;Kingston HG Mills","doi":"10.1016/j.coi.2023.102355","DOIUrl":null,"url":null,"abstract":"<div><p>Whooping cough, caused by <em>Bordetella pertussis,</em> is still a major cause of morbidity and mortality worldwide. Current acellular pertussis (aP) vaccines induce potent circulating IgG and prevent severe disease in children/adults and in infants born to vaccinated mothers. However, they do not prevent nasal infection, allowing asymptomatic transmission of <em>B. pertussis</em>. Studies in animal models have demonstrated that, unlike natural infection, immunization with aP vaccines fails to induce secretory immunoglobulin A (IgA) or interleukin-17 (IL-17)-secreting tissue-resident memory CD4 T (T<sub>RM</sub>) cells, required for sustained sterilizing immunity in the nasal mucosa. Live-attenuated vaccines or aP vaccines formulated with novel adjuvants that induce respiratory IgA and T<sub>RM</sub> cells, especially when delivered by the nasal route, are in development and have considerable promise as next-generation vaccines against pertussis.</p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":null,"pages":null},"PeriodicalIF":6.6000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nasal vaccines for pertussis\",\"authors\":\"Pauline Schmitt ,&nbsp;Lisa Borkner ,&nbsp;Seyed Davoud Jazayeri ,&nbsp;Karen N McCarthy ,&nbsp;Kingston HG Mills\",\"doi\":\"10.1016/j.coi.2023.102355\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Whooping cough, caused by <em>Bordetella pertussis,</em> is still a major cause of morbidity and mortality worldwide. Current acellular pertussis (aP) vaccines induce potent circulating IgG and prevent severe disease in children/adults and in infants born to vaccinated mothers. However, they do not prevent nasal infection, allowing asymptomatic transmission of <em>B. pertussis</em>. Studies in animal models have demonstrated that, unlike natural infection, immunization with aP vaccines fails to induce secretory immunoglobulin A (IgA) or interleukin-17 (IL-17)-secreting tissue-resident memory CD4 T (T<sub>RM</sub>) cells, required for sustained sterilizing immunity in the nasal mucosa. Live-attenuated vaccines or aP vaccines formulated with novel adjuvants that induce respiratory IgA and T<sub>RM</sub> cells, especially when delivered by the nasal route, are in development and have considerable promise as next-generation vaccines against pertussis.</p></div>\",\"PeriodicalId\":11361,\"journal\":{\"name\":\"Current Opinion in Immunology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0952791523000742\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0952791523000742","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

百日咳杆菌引起的百日咳仍然是全世界发病率和死亡率的主要原因。目前的无细胞百日咳(aP)疫苗可诱导有效的循环IgG,并可预防儿童/成人和接种疫苗的母亲所生婴儿的严重疾病。然而,它们不能预防鼻腔感染,从而导致百日咳杆菌的无症状传播。动物模型研究表明,与自然感染不同,aP疫苗免疫不能诱导分泌型免疫球蛋白A(IgA)或白细胞介素17(IL-17)分泌的组织驻留记忆CD4 T(TRM)细胞,这是鼻粘膜持续杀菌免疫所必需的。减毒活疫苗或由诱导呼吸道IgA和TRM细胞的新型佐剂配制的aP疫苗,特别是当通过鼻腔途径递送时,正在开发中,作为下一代百日咳疫苗具有相当大的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Nasal vaccines for pertussis

Whooping cough, caused by Bordetella pertussis, is still a major cause of morbidity and mortality worldwide. Current acellular pertussis (aP) vaccines induce potent circulating IgG and prevent severe disease in children/adults and in infants born to vaccinated mothers. However, they do not prevent nasal infection, allowing asymptomatic transmission of B. pertussis. Studies in animal models have demonstrated that, unlike natural infection, immunization with aP vaccines fails to induce secretory immunoglobulin A (IgA) or interleukin-17 (IL-17)-secreting tissue-resident memory CD4 T (TRM) cells, required for sustained sterilizing immunity in the nasal mucosa. Live-attenuated vaccines or aP vaccines formulated with novel adjuvants that induce respiratory IgA and TRM cells, especially when delivered by the nasal route, are in development and have considerable promise as next-generation vaccines against pertussis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
13.30
自引率
1.40%
发文量
94
审稿时长
67 days
期刊介绍: Current Opinion in Immunology aims to stimulate scientifically grounded, interdisciplinary, multi-scale debate and exchange of ideas. It contains polished, concise and timely reviews and opinions, with particular emphasis on those articles published in the past two years. In addition to describing recent trends, the authors are encouraged to give their subjective opinion of the topics discussed. In Current Opinion in Immunology we help the reader by providing in a systematic manner: 1. The views of experts on current advances in their field in a clear and readable form. 2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications. Current Opinion in Immunology will serve as an invaluable source of information for researchers, lecturers, teachers, professionals, policy makers and students. Current Opinion in Immunology builds on Elsevier''s reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health. It is a companion to the new Gold Open Access journal Current Research in Immunology and is part of the Current Opinion and Research(CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists'' workflow.
期刊最新文献
Tissue-resident memory cells in antitumoral immunity and cancer immunotherapy Metabolic requirements of type 2 lymphocytes in allergic disease The immunometabolic roots of aging Host-encoded antivirulence defenses: host physiologies teach pathogens to play nice Metabolism and macrophages in the tumor microenvironment
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1